With the rapid progress in molecular biology, there is a great need to train academic surgical oncologists that can not only deliver state of the art surgical care, but can also lead multidisciplinary teams and research programs leveraging molecular oncology and new technologies. To address the national shortage of surgical investigators focused on surgical oncology, the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center has dedicated its T32 training program to producing academic surgical oncologists. The long-term objective is to train surgical residents and surgical oncology fellows in the essential research skills necessary to be productive independent surgical investigators, and leaders in surgical oncology. Moreover, we are committed to providing T32 training to groups that are underrepresented in academic surgical oncology, including minority individuals and women. Training is offered to postdoctoral M.D. or M.D. Ph.D. fellows either during a 24-month hiatus from general surgery residency training or during a three-year clinical/research fellowship in surgical oncology that begins after general surgery residency. Our T32 training program has been highly successful in achieving its goals and is now entering its 25th year. Upon completion of their residency training, most of our T32 research fellows either started fellowship training, or accepted academic surgical positions. Upon completion of their surgical oncology fellowship training, all of our T32 clinical/research fellows entered academic Surgical Oncology positions. Our T32 program provides research opportunities in a broad range of basic oncologic disciplines, including cancer biology, molecular oncology, cell signaling, nanotechnology, molecular therapeutics, biomarker development and validation, clinical trials, clinical effectiveness and outcomes research. This academic training program allows us to train surgeons with a diverse set of unique skills, increasing the likelihood of trainees obtaining an academic position upon completion of training. Training in biostatistics, and the responsible conduct of research, and a rich array of seminars and graduate courses are integral to this T32 program. The T32 program faculty includes established surgical investigators and full-time academic basic science researchers, all of whom have peer-reviewed grant support. Programs at the Texas Medical Center provide our trainees access to resources and potential collaborators at six academic institutions. Thus, the University of Texas MD Anderson Cancer Center is a highly stimulating environment for aspiring academic surgical oncologists.

Public Health Relevance

With the rapid progress in molecular biology, there is a great need to train academic surgical oncologists that can not only deliver state of the art surgical care, but can also lead multidisciplinary teams as well as research programs leveraging molecular oncology and new technologies. The goal of this T32 training program is to train surgical trainees in the essential research skills necessary to be productive independent surgical investigators and leaders in surgical oncology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009599-27
Application #
8796825
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
1994-05-25
Project End
2018-01-31
Budget Start
2015-02-01
Budget End
2016-01-31
Support Year
27
Fiscal Year
2015
Total Cost
$391,018
Indirect Cost
$37,373
Name
University of Texas MD Anderson Cancer Center
Department
Surgery
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Wang, Yinghong; Wiesnoski, Diana H; Helmink, Beth A et al. (2018) Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med :
Helmink, Beth A; Gaudreau, Pierre-Olivier; Wargo, Jennifer A (2018) Immune Checkpoint Blockade across the Cancer Care Continuum. Immunity 48:1077-1080
Keung, Emily Z; Ikoma, Naruhiko; Benjamin, Robert et al. (2018) The clinical behavior of well differentiated liposarcoma can be extremely variable: A retrospective cohort study at a major sarcoma center. J Surg Oncol 117:1799-1805
Koay, Eugene J; Lee, Yeonju; Cristini, Vittorio et al. (2018) A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24:5883-5894
Keung, Emily Z; Tsai, Jen-Wei; Ali, Ali M et al. (2018) Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology 7:e1385689
Keung, Emily Z; Chiang, Yi-Ju; Cormier, Janice N et al. (2018) Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. Cancer 124:4495-4503
Narula, Nisha; Kim, Bradford J; Davis, Catherine H et al. (2018) A proactive outreach intervention that decreases readmission after hepatectomy. Surgery 163:703-708
Cloyd, Jordan M; Mizuno, Takashi; Kawaguchi, Yoshikuni et al. (2018) Comprehensive Complication Index Validates Improved Outcomes Over Time Despite Increased Complexity in 3707 Consecutive Hepatectomies. Ann Surg :
Dood, Robert L; Fleming, Nicole D; Coleman, Robert L et al. (2018) When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer 28:1485-1490
Wang, Yinghong; Wiesnoski, Diana H; Helmink, Beth A et al. (2018) Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24:1804-1808

Showing the most recent 10 out of 202 publications